Published in Bone Marrow Transplant on January 19, 2009
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood (2009) 1.25
Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant (2010) 1.03
Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol (2013) 0.87
Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant (2015) 0.84
Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biol Blood Marrow Transplant (2015) 0.80
Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant (2015) 0.78
Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant (2014) 0.76
A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipients. Ups J Med Sci (2010) 0.75
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet (2016) 0.75
Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation. Bone Marrow Transplant (2014) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet (1998) 2.42
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet (2007) 1.79
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant (2007) 1.76
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant (2006) 1.54
Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant (2005) 1.50
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2006) 1.47
The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol (2002) 1.38
Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit (2006) 1.30
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol (1996) 1.29
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood (2005) 1.27
Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol (2006) 1.25
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2005) 1.23
Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther (2005) 1.18
Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation (2008) 1.16
Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos (2004) 1.15
Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit (1999) 1.15
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol (1997) 1.12
Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem (1995) 1.11
A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant (2004) 1.05
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther (2008) 1.05
Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation (1999) 1.02
Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit (2007) 0.94
Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant (2008) 0.93
Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. Transplant Proc (1997) 0.89
Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem (2000) 0.88
Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol (2007) 0.87
Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant (2001) 0.87
Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant (2000) 0.84
Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation (1998) 0.82
Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol (2005) 0.82
Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). J Clin Pharmacol (2008) 0.80
Individualization of mycophenolate mofetil dose in renal transplant recipients. Expert Opin Pharmacother (2006) 0.80
Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit (2004) 0.78
Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol (2000) 0.78
Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin. Transplantation (2007) 0.77
The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics (2003) 32.92
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun (1997) 7.87
Agrobacterium conjugation and gene regulation by N-acyl-L-homoserine lactones. Nature (1993) 6.55
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity (2000) 3.84
MEDTAG: tag-like semantics for medical document indexing. Proc AMIA Symp (1999) 3.75
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Transfer of virulence in vivo and in vitro in Agrobacterium. Nature (1977) 3.23
Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.20
A revision of Rhizobium Frank 1889, with an emended description of the genus, and the inclusion of all species of Agrobacterium Conn 1942 and Allorhizobium undicola de Lajudie et al. 1998 as new combinations: Rhizobium radiobacter, R. rhizogenes, R. rubi, R. undicola and R. vitis. Int J Syst Evol Microbiol (2001) 2.97
All three SOS-inducible DNA polymerases (Pol II, Pol IV and Pol V) are involved in induced mutagenesis. EMBO J (2000) 2.77
Host cellular immune response to pneumococcal lung infection in mice. Infect Immun (2000) 2.74
Reconciling users' needs and formal requirements: issues in developing a reusable ontology for medicine. IEEE Trans Inf Technol Biomed (1998) 2.69
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41
Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination. Infect Immun (1976) 2.27
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood (1996) 2.19
Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol (2001) 2.03
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
Correlation between body mass index and orthodontic treatment outcome. Angle Orthod (2012) 1.99
Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (1994) 1.98
The yeast KRE5 gene encodes a probable endoplasmic reticulum protein required for (1----6)-beta-D-glucan synthesis and normal cell growth. Mol Cell Biol (1990) 1.96
Capillary tube assay for staphylococcal enterotoxins A, B, and C. Appl Microbiol (1971) 1.95
Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun (2001) 1.86
Guns and suicide: possible effects of some specific legislation. Am J Psychiatry (1990) 1.86
Validity of the rapid buffering approximation near a point source of calcium ions. Biophys J (1996) 1.84
Arginine catabolism: a new function of both octopine and nopaline Ti-plasmids of Agrobacterium. Mol Gen Genet (1979) 1.84
Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med (1997) 1.82
Differences in the hemodynamic response to event-related motor and visual paradigms as measured by near-infrared spectroscopy. Neuroimage (2003) 1.82
Climate change and the integrity of science. Science (2010) 1.80
Adrenergic neuron blockade by clonidine: comparison with guanethidine and local anesthetics. Arch Int Pharmacodyn Ther (1972) 1.78
A selective medium for Agrobacterium radiobacter biotype 2. J Appl Bacteriol (1971) 1.74
Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res (1999) 1.70
Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet (2000) 1.61
Female phenotype and multiple abnormalities in sibs with a Y chromosome and partial X chromosome duplication: H--Y antigen and Xg blood group findings. J Med Genet (1980) 1.56
The association between tuberous sclerosis and insulinoma. AJNR Am J Neuroradiol (1995) 1.52
Tn5 insertions in the agrocin 84 plasmid: the conjugal nature of pAgK84 and the locations of determinants for transfer and agrocin 84 production. Plasmid (1985) 1.51
Potential role of retinoids in the therapy of renal disease. Nephrol Dial Transplant (2001) 1.51
Hepatitis B core antigen. Detection of antibody by radioimmunoprecipitation. J Immunol (1975) 1.50
A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. Gut (2009) 1.49
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis. Kidney Int (2001) 1.49
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant (2000) 1.48
A diffusible compound can enhance conjugal transfer of the Ti plasmid in Agrobacterium tumefaciens. J Bacteriol (1991) 1.47
Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. J Med Microbiol (1995) 1.45
Defibrillators in general practice. Br Med J (Clin Res Ed) (1984) 1.45
How community doctors can have easy access to the medical literature. Can Med Assoc J (1981) 1.43
Composition of the immunoglobulin classic antigen-binding site regulates allergic airway inflammation in a murine model of experimental asthma. Clin Exp Allergy (2009) 1.43
Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis (2001) 1.42
Radiologic interpretation of lumbar vertebral rotation. Spine (Phila Pa 1976) (1991) 1.41
B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant (1999) 1.41
Spontaneous dissection of native coronary arteries. Heart (2005) 1.41
Agrocin 84 is a 6-N-phosphoramidate of an adenine nucleotide analogue. Nature (1977) 1.40
Why history is the key in the diagnosis of vertigo. Practitioner (2000) 1.40
On the presence and distribution of alpha-adrenoceptors in the heart of various mammalian species. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.40
Repression of c-fos and c-jun gene expression is not part of AT2 receptor coupled signal transduction. J Mol Med (Berl) (1998) 1.39
Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood (1998) 1.39
Patents versus transplants. Nature (1996) 1.38
Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat Genet (1999) 1.38
Differentiation of H1- and H2-receptors mediating positive chrono- and inotropic responses to histamine on atrial preparations of the guinea-pig. Agents Actions (1974) 1.36
Reversed-phase ion-pair liquid chromatographic procedure for the simultaneous analysis of S-adenosylmethionine, its metabolites and the natural polyamines. J Chromatogr (1982) 1.36
Accumulation of decarboxylated S-adenosyl-L-methionine in mammalian cells as a consequence of the inhibition of putrescine biosynthesis. Eur J Biochem (1982) 1.30
Stress fibers in the splenic sinus endothelium in situ: molecular structure, relationship to the extracellular matrix, and contractility. J Cell Biol (1986) 1.30
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun (2000) 1.28
Mediation of NGF signaling by post-translational inhibition of HES-1, a basic helix-loop-helix repressor of neuronal differentiation. Genes Dev (1997) 1.28
Effect of phentolamine on noradrenaline uptake and release. Naunyn Schmiedebergs Arch Pharmakol (1971) 1.27
Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet (2005) 1.26
Caspase 3 cleavage of the Ste20-related kinase SLK releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region. Mol Cell Biol (2000) 1.26
Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother (1992) 1.24
Genes involved in copper resistance influence survival of Pseudomonas aeruginosa on copper surfaces. J Appl Microbiol (2009) 1.23
[Quantitative studies on the importance of vasodilator receptors in the skin during circulatory homeostasis in waking humans. I. Character of the arterial blood pressure and heart rate with respect to gradual transmural blood pressure change in the carotid sinus region]. Pflugers Arch Gesamte Physiol Menschen Tiere (1967) 1.23
Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology (1999) 1.23
Mechanisms of tandem repeat instability in bacteria. Mutat Res (2006) 1.23
Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-kappaB activation. Oncogene (2001) 1.22
Veterans aging cohort three-site study (VACS 3): overview and description. J Clin Epidemiol (2001) 1.22
Identification of p60 antibodies in human sera and presentation of this listerial antigen on the surface of attenuated salmonellae by the HlyB-HlyD secretion system. Infect Immun (1992) 1.22
Phosphotyrosine-independent binding of SHC to the NPLH sequence of murine protein-tyrosine phosphatase-PEST. Evidence for extended phosphotyrosine binding/phosphotyrosine interaction domain recognition specificity. J Biol Chem (1996) 1.22
Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun (1977) 1.22
Consistent fat suppression with compensated spectral-spatial pulses. Magn Reson Med (1997) 1.21
Quantitative trait loci associated with parasitic infection in Scottish blackface sheep. Heredity (Edinb) (2006) 1.20
Is vasculitis in subacute bacterial endocarditis associated with ANCA? Lancet (1991) 1.20
Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res (1994) 1.20
Characteristics of the nopaline catabolic plasmid in Agrobacterium strains K84 and K1026 used for biological control of crown gall disease. Plasmid (1990) 1.20
Structural and functional MRIs disclose cerebellar pathologies in idiopathic downbeat nystagmus. Neurology (2007) 1.19
Demonstration in human atrial preparations of alpha-adrenoceptors mediating positive inotropic effects. Naunyn Schmiedebergs Arch Pharmacol (1978) 1.19
Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant (2006) 1.18
Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant (2012) 1.17
Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis (1992) 1.17
Biological control of crown gall: seed and root inoculation. J Appl Bacteriol (1974) 1.17
Influence of papaverine, D600, and nifedipine on the effects of noradrenaline and calcium on the isolated aorta and mesenteric artery of the rabbit. Naunyn Schmiedebergs Arch Pharmacol (1975) 1.17
Biopsies of the Janeway lesion of infective endocarditis. J Cutan Pathol (1979) 1.17
Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest (1993) 1.17
Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A (1992) 1.16
Efficacy and safety of repeated hepatocyte transplantation for significant liver repopulation in rodents. Gastroenterology (1996) 1.15